Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression - Oncogene
- ️Jiang, B-H
- ️Mon Feb 23 2015
Ferguson EC, Rathmell JC . New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci 2008; 33: 359–362.
Warburg O . On the origin of cancer cells. Science 1956; 123: 309–314.
Mazurek S, Eigenbrodt E . The tumor metabolome. Anticancer Res 2003; 23: 1149–1154.
Macintyre AN, Rathmell JC . PKM2 and the tricky balance of growth and energy in cancer. Mol Cell 2011; 42: 713–714.
Gao X, Wang H, Yang JJ, Liu X, Liu ZR . Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 2012; 45: 598–609.
Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 2011; 42: 719–730.
Iqbal MA, Bamezai RN . Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One 2012; 7: e36764.
Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230–233.
Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685–696.
Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732–744.
Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell 2012; 48: 771–784.
Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D . MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One 2011; 6: e28234.
Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012; 72: 1438–1448.
Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108: 4129–4134.
Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B . Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol 2010; 12: 1102–1112.
Jung CJ, Iyengar S, Blahnik KR, Ajuha TP, Jiang JX, Farnham PJ et al. Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS One 2011; 6: e27740.
Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915–928.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221–230.
Guler HP, Zapf J, Froesch ER . Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317: 137–140.
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 2013; 5: 3–13.
Zhang R, Li M, Zang W, Chen X, Wang Y, Li P et al. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour Biol 2014; 35: 837–844.
Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha. J Immunol 2010; 185: 7244–7251.
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ 2011; 18: 1702–1710.
Liu C, Rangnekar VM, Adamson E, Mercola D . Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 1998; 5: 3–28.
Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, Valen E et al. JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 2010 38: D105–D110.
Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008; 214: 17–24.
Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T . NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J 2005; 24: 128–137.
Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC . Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008; 452: 181–186.
Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011; 480: 118–122.
Kitamura K, Hatano E, Higashi T, Narita M, Seo S, Nakamoto Y et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 2011; 55: 846–857.
Schmidt M, Voelker HU, Kapp M, Krockenberger M, Dietl J, Kammerer U . Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol 2010; 136: 219–225.
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011; 24: 157–167.
Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A et al. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One 2012; 7: e46684.
Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wojdemann M, Johansen JS . Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer – five microRNAs in a prognostic index. World J Surg 2012; 36: 2699–2707.
Kwon OH, Kang TW, Kim JH, Kim M, Noh SM, Song KS et al. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 2012; 423: 38–44.